Literature DB >> 15388434

Effect of glycine on Helicobacter pylori in vitro.

Masaaki Minami1, Takafumi Ando, Shin-Nosuke Hashikawa, Keizo Torii, Tadao Hasegawa, Dawn A Israel, Kenji Ina, Kazuo Kusugami, Hidemi Goto, Michio Ohta.   

Abstract

Glycine is the simplest amino acid and is used as a metabolic product in some bacteria. However, an excess of glycine inhibits the growth of many bacteria, and it is used as a nonspecific antiseptic agent due to its low level of toxicity in animals. The effect of glycine on Helicobacter pylori is not precisely known. The present study was conducted to investigate (i) the effect of glycine on clarithromycin (CLR)-resistant and -susceptible strains of H. pylori, (ii) the effect of glycine in combination with amoxicillin (AMX), and (iii) the postantibiotic effect (PAE). The MIC at which 90% of strains are inhibited for glycine was almost 2.5 mg/ml for 31 strains of H. pylori, including CLR-resistant strains. We constructed isogenic CLR-resistant mutant strains by natural transformation and investigated the difference between clinical wild-type strains and isogenic mutants. There were no differences in the MICs between CLR-resistant and -susceptible strains or between clinical wild-type and mutant strains. The combination of AMX and glycine showed synergistic activity, with the minimum bactericidal concentration of AMX with glycine decreasing to 1/10 that of AMX alone. Glycine showed no PAE against H. pylori. These results suggest that glycine may be a useful antimicrobial agent against H. pylori not only alone but also in combination with antibacterial drugs for the treatment of H. pylori-associated diseases. Glycine may represent a component of a new type of eradication therapy for CLR-resistant H. pylori.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388434      PMCID: PMC521915          DOI: 10.1128/AAC.48.10.3782-3788.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Clarithromycin and omeprazole for Helicobacter pylori.

Authors:  R P Logan; P A Gummett; B T Hegarty; M M Walker; J H Baron; J J Misiewicz
Journal:  Lancet       Date:  1992-07-25       Impact factor: 79.321

2.  The complete genome sequence of the gastric pathogen Helicobacter pylori.

Authors:  J F Tomb; O White; A R Kerlavage; R A Clayton; G G Sutton; R D Fleischmann; K A Ketchum; H P Klenk; S Gill; B A Dougherty; K Nelson; J Quackenbush; L Zhou; E F Kirkness; S Peterson; B Loftus; D Richardson; R Dodson; H G Khalak; A Glodek; K McKenney; L M Fitzegerald; N Lee; M D Adams; E K Hickey; D E Berg; J D Gocayne; T R Utterback; J D Peterson; J M Kelley; M D Cotton; J M Weidman; C Fujii; C Bowman; L Watthey; E Wallin; W S Hayes; M Borodovsky; P D Karp; H O Smith; C M Fraser; J C Venter
Journal:  Nature       Date:  1997-08-07       Impact factor: 49.962

3.  The issue of the true postantibiotic effect.

Authors:  P A Majcherczyk
Journal:  J Antimicrob Chemother       Date:  1996-01       Impact factor: 5.790

4.  A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.

Authors:  M Asaka; T Sugiyama; M Kato; K Satoh; H Kuwayama; Y Fukuda; T Fujioka; T Takemoto; K Kimura; T Shimoyama; K Shimizu; S Kobayashi
Journal:  Helicobacter       Date:  2001-09       Impact factor: 5.753

5.  Antibiotic susceptibility of Helicobacter pylori in the Chinese population.

Authors:  J Yakoob; X Fan; G Hu; L Liu; Z Zhang
Journal:  J Gastroenterol Hepatol       Date:  2001-09       Impact factor: 4.029

6.  Restriction-modification system differences in Helicobacter pylori are a barrier to interstrain plasmid transfer.

Authors:  T Ando; Q Xu; M Torres; K Kusugami; D A Israel; M J Blaser
Journal:  Mol Microbiol       Date:  2000-09       Impact factor: 3.501

7.  Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori.

Authors:  J Labenz; E Gyenes; G H Rühl; G Börsch
Journal:  Am J Gastroenterol       Date:  1993-04       Impact factor: 10.864

8.  Improved electroporation and cloning vector system for gram-positive bacteria.

Authors:  G M Dunny; L N Lee; D J LeBlanc
Journal:  Appl Environ Microbiol       Date:  1991-04       Impact factor: 4.792

9.  Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori.

Authors:  R A Alm; L S Ling; D T Moir; B L King; E D Brown; P C Doig; D R Smith; B Noonan; B C Guild; B L deJonge; G Carmel; P J Tummino; A Caruso; M Uria-Nickelsen; D M Mills; C Ives; R Gibson; D Merberg; S D Mills; Q Jiang; D E Taylor; G F Vovis; T J Trust
Journal:  Nature       Date:  1999-01-14       Impact factor: 49.962

10.  Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group.

Authors:  E Bayerdörffer; A Neubauer; B Rudolph; C Thiede; N Lehn; S Eidt; M Stolte
Journal:  Lancet       Date:  1995-06-24       Impact factor: 79.321

View more
  11 in total

1.  In Vitro and In Vivo Antibacterial Activities of Patchouli Alcohol, a Naturally Occurring Tricyclic Sesquiterpene, against Helicobacter pylori Infection.

Authors:  Y F Xu; D W Lian; Y Q Chen; Y F Cai; Y F Zheng; P L Fan; W K Ren; L J Fu; Y C Li; J H Xie; H Y Cao; B Tan; Z R Su; P Huang
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

2.  Moraxella catarrhalis M35 is a general porin that is important for growth under nutrient-limiting conditions and in the nasopharynges of mice.

Authors:  Donna M Easton; Elke Maier; Roland Benz; A Ruth Foxwell; Allan W Cripps; Jennelle M Kyd
Journal:  J Bacteriol       Date:  2008-10-17       Impact factor: 3.490

3.  Antibacterial activities of almond skins on cagA-positive and-negative clinical isolates of Helicobacter pylori.

Authors:  Carlo Bisignano; Angela Filocamo; Erminia La Camera; Sebastiana Zummo; Maria Teresa Fera; Giuseppina Mandalari
Journal:  BMC Microbiol       Date:  2013-05-09       Impact factor: 3.605

4.  Bacteriolytic Activity Of Human Interleukin-2, Chicken Egg Lysozyme In The Presence Of Potential Effectors.

Authors:  P A Levashov; D A Matolygina; E D Ovchinnikova; D L Atroshenko; S S Savin; N G Belogurova; S A Smirnov; V I Tishkov; A V Levashov
Journal:  Acta Naturae       Date:  2017 Apr-Jun       Impact factor: 1.845

5.  Serine Hydroxymethyltransferase ShrA (PA2444) Controls Rugose Small-Colony Variant Formation in Pseudomonas aeruginosa.

Authors:  Mingming Pu; Lili Sheng; Sooyeon Song; Ting Gong; Thomas K Wood
Journal:  Front Microbiol       Date:  2018-02-27       Impact factor: 5.640

Review 6.  Effectiveness of Citrus Fruits on Helicobacter pylori.

Authors:  Giuseppina Mandalari; Carlo Bisignano; Santa Cirmi; Michele Navarra
Journal:  Evid Based Complement Alternat Med       Date:  2017-03-20       Impact factor: 2.629

7.  Contrasting amino acid profiles among permissive and non-permissive hosts of Candidatus Liberibacter asiaticus, putative causal agent of Huanglongbing.

Authors:  Mamoudou Sétamou; Olufemi J Alabi; Catherine R Simpson; John L Jifon
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

8.  The bacteriolytic activity of native and covalently immobilized lysozyme against Gram-positive and Gram-negative bacteria is differentially affected by charged amino acids and glycine.

Authors:  Pavel A Levashov; Darya A Matolygina; Ekaterina D Ovchinnikova; Irina Yu Adamova; Darya A Gasanova; Sergey A Smirnov; Vladimir A Nelyub; Natalya G Belogurova; Vladimir I Tishkov; Nikolay L Eremeev; Andrey V Levashov
Journal:  FEBS Open Bio       Date:  2019-01-28       Impact factor: 2.693

9.  Extracellular DNA released by glycine-auxotrophic Staphylococcus epidermidis small colony variant facilitates catheter-related infections.

Authors:  Junlan Liu; Zhen Shen; Jin Tang; Qian Huang; Ying Jian; Yao Liu; Yanan Wang; Xiaowei Ma; Qian Liu; Lei He; Min Li
Journal:  Commun Biol       Date:  2021-07-22

10.  Antibacterial activity of poly-l-arginine under different conditions.

Authors:  Mohaddeseh Sepahi; Razieh Jalal; Mansour Mashreghi
Journal:  Iran J Microbiol       Date:  2017-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.